ARTICLES

The pharmaceutical industry is evolving rapidly, with increasing regulatory demands, complex drug formulations, and the rise of biologics challenging traditional manufacturing methods. <br> How can companies stay ahead while ensuring efficiency, quality, and compliance? <br><br> This white paper delves into Quality by Design (QbD) and Design of Experiments (DoE)—two transformative methodologies that are revolutionising drug development. <br><br> Learn how top pharmaceutical companies like Strides Pharma leverage these approaches to enhance product quality, reduce risks, optimise processes, and streamline regulatory compliance. <br><br> Get insights on: <br> ✔️ QbD’s shift from reactive testing to built-in quality <br> ✔️ DoE’s role in faster, smarter drug formulation <br> ✔️ A real-world case study on arthritis medication development <br>

How does a pharma company stay ahead while serving global health needs? By making sustainability, ethics, and governance a core priority.

Europe’s nearly $500 billion pharmaceutical market is defined by complexity—fragmented regulations, pricing pressures, and shifting partner expectations. <br><br> At Strides Pharma, this has led to a clear shift: success is no longer driven by product alone, but by how effectively that product is delivered, across regulatory, quality, and supply chain layers. Read the full article to understand how execution is reshaping pharma partnerships in Europe.

Everyone sees the product launch. Few see the decisions that made it possible.

The game-changer for sustained growth

The pharmaceutical industry is facing an alarming trend: a dramatic increase in drug recalls. In 2022 alone, defective pharmaceutical units hit a five-year high, with January 2023 marking a significant spike in recalls– over 11.88 million units impacted due to critical deviations from Good Manufacturing Practices (GMP).

The Asia-Pacific (APAC) pharmaceutical market, already worth over USD 330 billion in 2024, is entering a new phase of maturity.

The U.S. over-the-counter (OTC) pharmaceutical market is expanding, but not without complexity. Valued at USD 42.4 billion in 2024, it is projected to grow at around 4.8 per cent CAGR through 2034, reflecting steady but margin-tightened growth.

Set to skyrocket from $367.1 billion in 2023 to $628 billion by 2032, the generic drug market is experiencing a boom! What's fueling this rapid expansion? A mix of factors: patent expirations, a rise in chronic diseases, and increased research investments.

Pharma growth is moving beyond volume. The next advantage lies in difficult-to-develop products, specialised capabilities and partnerships that create value competitors cannot easily replicate. Read the article to explore where the next growth opportunities may lie.

Global pharmaceutical markets have reached unprecedented scale. With nearly $1.6 trillion in annual revenue, the industry continues to draw companies toward new geographies and growth opportunities. Yet companies entering new geographies often meet a sharper commercial reality: large markets do not always translate into strong returns. Canada shows why market intelligence can matter more than market size.

Enters S&P yearbook in 1st year of participation